GlaxoSmithKline's
experimental Ebola vaccine could be tested on patients in clinical safety
trials in the US as soon as next week, as the death toll from the deadly virus
continues to rise in west Africa.
Britain's
largest drug-maker is developing the vaccine with the Vaccine Research Centre
of the National Institutes of Health (NIH) in the US. Phase-I trials have
received the green light from the US health watchdog, the Food and Drug
Administration, Bloomberg reported. This is the first test in humans to assess
safety and efficacy – whether the drug works in a similar way to how it does in
animals.